- Home
- NG vs GYRE Comparison
NG vs GYRE Comparison
Compare NG & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NG
- GYRE
- Stock Information
- Founded
- NG 1984
- GYRE 2002
- Country
- NG Canada
- GYRE United States
- Employees
- NG N/A
- GYRE N/A
- Industry
- NG Precious Metals
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- NG Basic Materials
- GYRE Health Care
- Exchange
- NG Nasdaq
- GYRE Nasdaq
- Market Cap
- NG 1.0B
- GYRE 1.1B
- IPO Year
- NG N/A
- GYRE N/A
- Fundamental
- Price
- NG $3.22
- GYRE $11.64
- Analyst Decision
- NG
- GYRE
- Analyst Count
- NG 0
- GYRE 0
- Target Price
- NG N/A
- GYRE N/A
- AVG Volume (30 Days)
- NG 2.0M
- GYRE 91.0K
- Earning Date
- NG 01-23-2025
- GYRE 03-25-2025
- Dividend Yield
- NG N/A
- GYRE N/A
- EPS Growth
- NG N/A
- GYRE N/A
- EPS
- NG N/A
- GYRE N/A
- Revenue
- NG N/A
- GYRE $105,033,000.00
- Revenue This Year
- NG N/A
- GYRE $25.32
- Revenue Next Year
- NG N/A
- GYRE $12.95
- P/E Ratio
- NG N/A
- GYRE N/A
- Revenue Growth
- NG N/A
- GYRE N/A
- 52 Week Low
- NG $2.23
- GYRE $8.26
- 52 Week High
- NG $4.88
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- NG 48.42
- GYRE 54.44
- Support Level
- NG $3.07
- GYRE $11.18
- Resistance Level
- NG $3.26
- GYRE $11.85
- Average True Range (ATR)
- NG 0.15
- GYRE 0.52
- MACD
- NG 0.01
- GYRE 0.14
- Stochastic Oscillator
- NG 67.31
- GYRE 83.91
About NG Novagold Resources Inc.
Novagold Resources Inc is a mineral exploration company engaged in the exploration and development of mineral properties. The company owns 50% of the Donlin Gold project, which is located in southwestern Alaska, approximately 20 kilometers north of the village of Crooked Creek on the Kuskokwim River.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.